Entrada Therapeutics Inc (TRDA) stock price

Entrada Therapeutics Inc (TRDA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $6.75 (-2.17%), Market cap $0.24B, 52-week low–high $5.02 ~ $16.03.

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated

Key metrics

Financial statements, price targets, institutional (13F) holdings and related news for Entrada Therapeutics Inc are updated in real time on BlackAll Trade.

Entrada Therapeutics Inc financial summary

Analyst outlook

Key ratios · profitability · growth

Frequently asked questions

What is the current Entrada Therapeutics Inc (TRDA) stock price?

Entrada Therapeutics Inc trades at $6.75 (-2.17%). Real-time quotes and charts are available on BlackAll Trade.

What is the Entrada Therapeutics Inc (TRDA) market cap?

Entrada Therapeutics Inc has a market cap of about $0.24B.

What does Entrada Therapeutics Inc (TRDA) do?

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have